Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Yoshihiro Ono

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1662-5131; OpenAlex author ID A5033354878. Sources: OpenAlex.

Their work

Papers
33 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers · 2022: 8 papers · 2023: 6 papers · 2024: 2 papers · 2025: 5 papers · 2026: 3 papers

Papers 33

  1. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  2. ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18960-9↗
  3. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  4. Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer. First author DOI 10.1007/s00464-025-12125-1↗
  5. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  6. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  7. Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17019-z↗
  8. ASO Author Reflections: Advancing the Superior Mesenteric Arterial Divestment for Locally Advanced Pancreatic Cancer: New Standard Procedure and Future Prospec… Co-author DOI 10.1245/s10434-025-17090-6↗
  9. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  10. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  11. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Co-author DOI 10.1007/s00423-023-02942-0↗
  12. Radical antegrade modular pancreatosplenectomy enhances local control of the disease in patients with left-sided pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.08.004↗
  13. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  14. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era. Co-author DOI 10.1016/j.hpb.2023.05.366↗
  15. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
  16. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  17. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreato… First author DOI 10.1007/s00268-022-06457-5↗
  18. Diabetogenic liver metastasis from pancreatic cancer: a case report. First author DOI 10.1186/s40792-022-01582-8↗
  19. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Co-author DOI 10.1245/s10434-021-10560-7↗
  20. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with … Co-author DOI 10.1245/s10434-022-11382-x↗
  21. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… First author DOI 10.1245/s10434-022-11471-x↗
  22. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗
  23. ASO Author Reflections: Histology-Based Supervised Machine Learning Model Can Predict Recurrence Pattern of Pancreatic Cancer. First author DOI 10.1245/s10434-022-11540-1↗
  24. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Co-author DOI 10.1245/s10434-022-11621-1↗
  25. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  26. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Co-author DOI 10.1016/j.pan.2020.11.026↗
  27. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. Co-author DOI 10.1093/bjs/znaa111↗
  28. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. Co-author DOI 10.1002/bjs5.50268↗
  29. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Co-author DOI 10.1007/s00423-019-01846-2↗
  30. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04203-2↗
  31. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. Co-author DOI 10.1007/s11605-018-3995-3↗
  32. Techniques for splenic vein reconstruction after pancreaticoduodenectomy with portal vein resection for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.017↗
  33. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. Co-author DOI 10.1007/s00268-012-1622-0↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Oba · 27 shared papers, 2019–2026 · strength 4.88
  2. Hiromichi Ito · 28 shared papers, 2019–2026 · strength 4.75
  3. Yu Takahashi · 26 shared papers, 2019–2026 · strength 4.11
  4. Yosuke Inoue · 24 shared papers, 2019–2026 · strength 3.94
  5. Akio Saiura · 17 shared papers, 2012–2024 · strength 2.33
  6. Masato Ozaka · 12 shared papers, 2021–2026 · strength 2.10
  7. Naoki Sasahira · 12 shared papers, 2021–2026 · strength 2.10
  8. Takashi Sasaki · 11 shared papers, 2021–2026 · strength 1.89
  9. Aya Maekawa · 6 shared papers, 2024–2026 · strength 1.22
  10. Manabu Takamatsu · 7 shared papers, 2021–2025 · strength 1.20
  11. Tomotaka Kato · 4 shared papers, 2022–2026 · strength 0.83
  12. Tatsunori Miyata · 3 shared papers, 2026 · strength 0.78
  13. Masaaki Iwatsuki · 3 shared papers, 2026 · strength 0.78
  14. Yosuke Inoue · 4 shared papers, 2024–2026 · strength 0.77
  15. Yu Takahashi · 3 shared papers, 2025 · strength 0.74
  16. Kojiro Omiya · 4 shared papers, 2023–2025 · strength 0.69
  17. Takafumi Mie · 4 shared papers, 2021–2025 · strength 0.60
  18. Tsuyoshi Takeda · 4 shared papers, 2021–2024 · strength 0.60
  19. Yuta Ushida · 4 shared papers, 2021–2022 · strength 0.57
  20. Ryota Ito · 2 shared papers, 2025 · strength 0.54
  21. Yuki Hirose · 3 shared papers, 2024–2025 · strength 0.53
  22. Yu Takahashi · 2 shared papers, 2023–2026 · strength 0.46
  23. Hiromichi Ito · 2 shared papers, 2023–2026 · strength 0.46
  24. Koki Hayashi · 2 shared papers, 2022 · strength 0.36
  25. Shoki Sato · 2 shared papers, 2023–2024 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.